TABLE 3.
In vitro activities of plazomicin and comparators against ESBL-producing and non-ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates
| Organism (no. of isolates) and agent | MIC (µg/ml) |
% of isolates |
||||
|---|---|---|---|---|---|---|
| 50% | 90% | Range | Susceptible | Intermediate | Resistant | |
| ESBL-producing Escherichia coli (343) | ||||||
| Plazomicin | 0.5 | 1 | 0.25 to 2 | 100 | 0 | 0 |
| Amikacin | 2 | 8 | ≤1 to 64 | 98.8 | 0.9 | 0.3 |
| Gentamicin | ≤0.5 | >32 | ≤0.5 to >32 | 67.1 | 1.7 | 31.2 |
| Tobramycin | 4 | 32 | ≤0.5 to >64 | 55.7 | 7.0 | 37.3 |
| Cefazolin | >128 | >128 | 4 to >128 | 0 | 0.3 | 99.7 |
| Ceftazidime | 16 | >32 | 0.5 to >32 | 31.8 | 11.6 | 56.6 |
| Ceftriaxone | >64 | >64 | ≤0.25 to >64 | 2.6 | 1.5 | 95.9 |
| Ciprofloxacin | >16 | >16 | ≤0.06 to >16 | 12.5 | 0 | 87.5 |
| Ertapenem | ≤0.03 | 0.12 | ≤0.03 to >32 | 98.0 | 0.8 | 1.2 |
| Meropenem | ≤0.03 | 0.06 | ≤0.03 to 32 | 99.7 | 0 | 0.3 |
| Piperacillin-tazobactam | 4 | 16 | ≤1 to >512 | 92.7 | 3.8 | 3.5 |
| Tigecycline | 0.25 | 1 | 0.12 to 2 | 100 | 0 | 0 |
| Trimethoprim-sulfamethoxazole | >8 | >8 | ≤0.12 to >8 | 32.4 | NAa | 67.6 |
| Non-ESBL-producing Escherichia coli (2,751) | ||||||
| Plazomicin | 0.5 | 1 | ≤0.12 to >64 | 99.4 | 0.5 | 0.1 |
| Amikacin | 2 | 4 | ≤1 to >64 | 99.8 | 0.1 | 0.1 |
| Gentamicin | ≤0.5 | 1 | ≤0.5 to >32 | 93.8 | 0.2 | 6.0 |
| Tobramycin | ≤0.5 | 1 | ≤0.5 to >64 | 96.3 | 2.1 | 1.6 |
| Cefazolin | 2 | 8 | ≤0.5 to >128 | 79.7 | 9.9 | 10.4 |
| Ceftazidime | ≤0.25 | 0.5 | ≤0.25 to >32 | 98.1 | 0.3 | 1.6 |
| Ceftriaxone | ≤0.25 | ≤0.25 | ≤0.25 to >64 | 98.0 | 0.2 | 1.8 |
| Ciprofloxacin | ≤0.06 | >16 | ≤0.06 to >16 | 83.1 | 0.1 | 16.8 |
| Ertapenem | ≤0.03 | ≤0.03 | ≤0.03 to 2 | 99.8 | 0.1 | 0.1 |
| Meropenem | ≤0.03 | ≤0.03 | ≤0.03 to 0.25 | 100 | 0 | 0 |
| Piperacillin-tazobactam | 2 | 4 | ≤1 to >512 | 97.6 | 1.3 | 1.1 |
| Tigecycline | 0.25 | 0.5 | ≤0.03 to 4 | 99.9 | 0.1 | 0 |
| Trimethoprim-sulfamethoxazole | ≤0.12 | >8 | ≤0.12 to >8 | 78.1 | NA | 21.9 |
| ESBL-producing Klebsiella pneumoniae (73) | ||||||
| Plazomicin | 0.25 | 0.5 | ≤0.12 to 4 | 98.6 | 1.4 | 0 |
| Amikacin | 2 | 8 | ≤1 to 16 | 100 | 0 | 0 |
| Gentamicin | 16 | >32 | ≤0.5 to >32 | 49.3 | 0 | 50.7 |
| Tobramycin | 8 | 32 | ≤0.5 to >64 | 37.0 | 24.6 | 38.4 |
| Cefazolin | >128 | >128 | 8 to >128 | 0 | 0 | 100 |
| Ceftazidime | >32 | >32 | 0.5 to >32 | 17.8 | 5.5 | 76.7 |
| Ceftriaxone | >64 | >64 | ≤0.25 to >64 | 4.1 | 0 | 95.9 |
| Ciprofloxacin | 8 | >16 | ≤0.06 to >16 | 23.3 | 10.9 | 65.8 |
| Ertapenem | 0.12 | 8 | ≤0.03 to >32 | 82.2 | 5.5 | 12.3 |
| Meropenem | ≤0.03 | 0.5 | ≤0.03 to 16 | 93.2 | 2.7 | 4.1 |
| Piperacillin-tazobactam | 16 | >512 | 2 to >512 | 61.6 | 15.1 | 23.3 |
| Tigecycline | 1 | 2 | 0.5 to 4 | 91.8 | 8.2 | 0 |
| Trimethoprim-sulfamethoxazole | >8 | >8 | ≤0.12 to >8 | 6.8 | NA | 93.2 |
| Non-ESBL-producing Klebsiella pneumoniae (966) | ||||||
| Plazomicin | 0.25 | 0.5 | ≤0.12 to >64 | 99.9 | 0 | 0.1 |
| Amikacin | ≤1 | 2 | ≤1 to >64 | 99.9 | 0 | 0.1 |
| Gentamicin | ≤0.5 | ≤0.5 | ≤0.5 to >32 | 99.3 | 0 | 0.7 |
| Tobramycin | ≤0.5 | ≤0.5 | ≤0.5 to >64 | 98.9 | 0.9 | 0.2 |
| Cefazolin | 1 | 4 | ≤0.5 to >128 | 88.5 | 5.7 | 5.8 |
| Ceftazidime | ≤0.25 | 0.5 | ≤0.25 to >32 | 98.8 | 0.3 | 0.9 |
| Ceftriaxone | ≤0.25 | ≤0.25 | ≤0.25 to >64 | 98.6 | 0.1 | 1.3 |
| Ciprofloxacin | ≤0.06 | 0.25 | ≤0.06 to >16 | 96.8 | 1.0 | 2.2 |
| Ertapenem | ≤0.03 | ≤0.03 | ≤0.03 to 32 | 99.8 | 0 | 0.2 |
| Meropenem | ≤0.03 | 0.06 | ≤0.03 to 8 | 99.9 | 0 | 0.1 |
| Piperacillin-tazobactam | 2 | 8 | ≤1 to >512 | 98.1 | 0.7 | 1.2 |
| Tigecycline | 0.5 | 1 | 0.12 to >16 | 96.5 | 2.9 | 0.6 |
| Trimethoprim-sulfamethoxazole | ≤0.12 | 0.5 | ≤0.12 to >8 | 94.0 | NA | 6.0 |
a
NA, MIC breakpoint not applicable.